Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036608 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
A Phase 3 study of Chronic Hepatitis B, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00036608: Completed Phase 3 study of Chronic Hepatitis B, sponsored by Bristol-Myers Squibb.
NCT00036608 is a Phase 3 study of Chronic Hepatitis B that has completed, run by Bristol-Myers Squibb. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036608, a Phase 3 study of Chronic Hepatitis B, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
Conditions Studied
Interventions
- DRUG Entecavir
Study Locations (20)
California
- Local Investigator - La Jolla
- Local Investigator - Los Angeles
- Local Investigator - Los Angeles
- Local Investigator - Orange
- Local Investigator - San Diego
- Local Investigator - San Francisco
Florida
- Local Investigator - Miami
- Local Investigator - Miami Beach
Georgia
- Local Investigator - Atlanta
- Local Investigator - Atlanta
Illinois
- Local Investigator - Chicago
- Local Investigator - Chicago
Alabama
- Local Investigator - Birmingham
Arizona
- Local Investigator - Tucson
Connecticut
- Local Investigator - Farmington
Hawaii
- Local Investigator - Honolulu
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
What the finished NCT00036608 record still lists
NCT00036608 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 1 intervention - of which Entecavir is the first listed.
NCT00036608 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00036608 about?
NCT00036608 is a clinical study titled "A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine". The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.
What is the current status of trial NCT00036608?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-01. Estimated completion is 2005-02.
What conditions does trial NCT00036608 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
What interventions are being tested in trial NCT00036608?
The interventions under investigation include: Entecavir (DRUG).
Who is sponsoring clinical trial NCT00036608?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00036608 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection
ACTIVE NOT RECRUITING · Phase 3
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed
COMPLETED · Phase 3
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia